


### In the Claims

Claims 1-30 are pending in this Application.

Original Claims 1-30 are canceled.

Claims 31-58 are new.

31. (new) A compound according to formula I,



or a pharmaceutically acceptable salt or a stereoisomer, thereof, wherein,

A is a five- to ten-membered ring containing up to three heteroatoms; provided A is not a saturated alicyclic when X<sup>2</sup> is =N-, X<sup>3</sup> is -O-, and A is a pyridin-4-yl;

R<sup>1</sup> is selected from -H, halo, trihalomethyl, -CN, -NO<sub>2</sub>, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -S(O)<sub>0-2</sub>R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=O)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, alkoxy, C<sub>1-6</sub> alkyl, aryl, aryl C<sub>1-6</sub> alkyl, heterocyclyl, and heterocyclyl C<sub>1-6</sub> alkyl;

two adjacent of R<sup>1</sup>, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to four of R<sup>10</sup>;

R<sup>2</sup> and R<sup>3</sup>, together with the annular atoms to which they are attached, form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to five of R<sup>6</sup>;

each R<sup>4</sup> is selected from -H; C<sub>1-6</sub> alkyl optionally substituted with 1, 2, or 3 halogen; C<sub>1-6</sub> alkyl optionally substituted with alkoxy; C<sub>1-6</sub> alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and *N*-methyl-pyrrolidin-3-yl; aryl; aryl C<sub>1-6</sub> alkyl; heterocyclyl; and heterocyclyl C<sub>1-6</sub> alkyl where the heterocyclyl is

optionally substituted with alkyl, acyl,  $\text{NH}_2$ , alkylamino, dialkylamino, heterocyclyl, cyclohexyl,  $-\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{C}(\text{O})\text{NHCH}(\text{CH}_3)_2$ , or  $-\text{CH}_2\text{OCH}_3$ ;

two of  $\text{R}^4$ , when taken together with a common nitrogen to which they are attached, form an five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

each  $\text{R}^5$  is selected from  $-\text{H}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{OR}^4$ ,  $-\text{S}(\text{O})_{0-2}\text{R}^4$ ,  $-\text{CO}_2\text{R}^4$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl, and  $\text{C}_{2-6}$  alkynyl;

Y is  $=\text{N}-$  or  $=\text{C}(\text{R}^8)-$ ;

$\text{X}^1$  and  $\text{X}^2$  are each independently either  $=\text{N}-$  or  $=\text{C}(\text{R}^9)-$ ;

$\text{X}^3$  is selected from  $-\text{N}(\text{R}^7)-$ ,  $-\text{O}-$ , and  $-\text{S}-$ ;

$\text{R}^7$  is hydrogen;

each of  $\text{R}^6$ ,  $\text{R}^8$ , and  $\text{R}^{10}$  is independently selected from  $-\text{H}$ , halo, trihalomethyl,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{OR}^4$ ,  $-\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{S}(\text{O})_{0-2}\text{R}^4$ ,  $-\text{SO}_2\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{CO}_2\text{R}^4$ ,  $-\text{C}(=\text{O})\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{C}(=\text{NR}^5)\text{N}(\text{R}^4)\text{R}^4$ ,  $-\text{C}(=\text{NR}^5)\text{R}^4$ ,  $-\text{N}(\text{R}^4)\text{SO}_2\text{R}^4$ ,  $-\text{N}(\text{R}^4)\text{C}(\text{O})\text{R}^4$ ,  $-\text{C}(=\text{O})\text{R}^4$ , optionally substituted alkoxy,  $\text{C}_{1-6}$  alkyl, aryl, aryl  $\text{C}_{1-6}$  alkyl, heterocyclyl, and heterocyclyl  $\text{C}_{1-6}$  alkyl;

two adjacent of  $\text{R}^6$ , together with the annular atoms to which they are attached, can form a five- to seven-membered ring containing up to two heteroatoms; and


each  $\text{R}^9$  is independently selected from  $-\text{H}$ ; halo; trihalomethyl;  $-\text{CN}$ ;  $-\text{NO}_2$ ;  $-\text{OR}^4$ ;  $-\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{S}(\text{O})_{0-2}\text{R}^4$ ;  $-\text{SO}_2\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{CO}_2\text{R}^4$ ;  $-\text{C}(=\text{O})\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{C}(=\text{NR}^5)\text{N}(\text{R}^4)\text{R}^4$ ;  $-\text{C}(=\text{NR}^5)\text{R}^4$ ;  $-\text{N}(\text{R}^4)\text{SO}_2\text{R}^4$ ;  $-\text{N}(\text{R}^4)\text{C}(\text{O})\text{R}^4$ ;  $-\text{C}(=\text{O})\text{R}^4$ ; alkoxy;  $\text{C}_{1-6}$  alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl  $\text{C}_{1-6}$  alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with  $-\text{C}(\text{O})\text{Ot-Bu}$ ; and heterocyclyl  $\text{C}_{1-6}$  alkyl; provided when  $\text{R}^9$  is aryl, heteroaryl,  $-\text{C}(\text{H})=\text{C}(\text{H})\text{R}$  or  $-\text{C}(\text{H})=\text{NR}$ , where R is an

optionally substituted alkyl, cycloalkyl, heteroalicyclic, aryl, or heteroaryl, then Y is not =C(H)-.

32. **(new)** The compound according to claim 31, wherein the five- to six-membered ring formed by R<sup>2</sup> and R<sup>3</sup> is an aryl or a heteroaryl optionally substituted with up to five of R<sup>6</sup>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

33. **(new)** The compound according to claim 32, wherein the five- to six-membered ring formed by R<sup>2</sup> and R<sup>3</sup> is phenyl or pyridyl optionally substituted with up to five of R<sup>6</sup>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

34. **(new)** The compound according to claim 33, of formula II,



or a pharmaceutically acceptable salt or stereoisomer, thereof.

35. **(new)** The compound according to claim 34, wherein X<sup>1</sup> is =C(R<sup>9</sup>)-, X<sup>2</sup> is =N-, X<sup>3</sup> is -N(R<sup>7</sup>)-, and R<sup>7</sup> is hydrogen; or a pharmaceutically acceptable salt or stereoisomer, thereof.


36. **(new)** The compound according to claim 35, wherein Y is =N-; or a pharmaceutically acceptable salt or stereoisomer, thereof.

37. **(new)** The compound according to claim 36, wherein A is either a six- to ten-membered aryl or a five- to ten-membered heteroaryl containing up to three heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

38. **(new)** The compound according to claim 37, wherein A is either a six-membered aryl or a five- or six-membered heteroaryl containing up to three heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

39. **(new)** The compound according to claim 38, wherein  $R^1$  is selected from -H, halo, trihalomethyl, -CN, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -SO<sub>2</sub>N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)N(R<sup>4</sup>)R<sup>4</sup>, -C(=NR<sup>5</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, alkoxy, C<sub>1-6</sub> alkyl, heterocyclyl, and heterocyclyl C<sub>1-6</sub> alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.


40. **(new)** The compound according to claim 39, of formula III,




III

wherein  $R^7$  is hydrogen and at least one of  $R^1$  is -OH; or a pharmaceutically acceptable salt or stereoisomer, thereof.

41. **(new)** The compound according to claim 40, wherein the compound is either of Formula IIa or IIIb:



IIIa



IIIb

or a pharmaceutically acceptable salt or stereoisomer, thereof.

42. **(new)** The compound according to claim 41, wherein  $R^9$  is selected from -H; trihalomethyl; C<sub>1-6</sub> alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C<sub>1-6</sub> alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-

Bu; and heterocyclyl C<sub>1-6</sub> alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

43. **(new)** The compound according to claim 42, wherein R<sup>6</sup> is selected from -H, halo, trihalomethyl, -CN, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -C(=O)N(R<sup>4</sup>)R<sup>4</sup>, -N(R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, -N(R<sup>4</sup>)C(O)R<sup>4</sup>, -C(=O)R<sup>4</sup>, C<sub>1-6</sub> alkyl, heterocyclyl, heterocyclyl C<sub>1-6</sub> alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R<sup>6</sup>, together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

44. **(new)** The compound according to claim 43, wherein R<sup>6</sup> is selected from -H, halo, -OR<sup>4</sup>, -N(R<sup>4</sup>)R<sup>4</sup>, C<sub>1-6</sub> alkyl, heterocyclyl, heterocyclyl C<sub>1-6</sub> alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R<sup>6</sup>, together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

45. **(new)** The compound according to claim 44, wherein at least one of R<sup>6</sup> is -OR<sup>4</sup> and R<sup>4</sup> is C<sub>1-6</sub> alkyl optionally substituted with 1, 2, or 3 halogen; C<sub>1-6</sub> alkyl optionally substituted with alkoxy; C<sub>1-6</sub> alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, and *N*-methyl-pyrrolidin-3-yl; and heterocyclyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH<sub>2</sub>, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>C(O)NHCH(CH<sub>3</sub>)<sub>2</sub>, or -CH<sub>2</sub>OCH<sub>3</sub>; or a pharmaceutically acceptable salt or stereoisomer, thereof.

46. **(new)** The compound according to claim 45, wherein at least one of R<sup>1</sup> is halo or methyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

47. **(new)** The compound according to claim 46, wherein R<sup>9</sup> is selected from -H, trihalomethyl, and C<sub>1-6</sub> alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.


48. **(new)** The compound according to claim 44, wherein at least one of  $R^6$  is  $-OR^4$  and  $R^4$  is heterocyclyl  $C_{1-6}$  alkyl where the heterocyclyl is a heteroalicyclic; or a pharmaceutically acceptable salt or stereoisomer, thereof.

49. **(new)** The compound according to claim 48, wherein said heteroalicyclic is selected from the group consisting of dioxolanyl, piperidiny, piperaziny, 2-oxopiperaziny, 2-oxopiperidiny, 2-oxopyrrolidiny, 2-oxoazepiny, azepiny, 4-piperidony, pyrrolidiny, morpholiny, quinuclidiny, tetrahydrofuryl, tetrahydropyranly, thiamorpholiny, thiamorpholiny sulfoxide, 2,5-diazabicyclo[2.2.1]heptanyl, and thiamorpholiny sulfone; or a pharmaceutically acceptable salt or stereoisomer, thereof.

50. **(new)** The compound according to claim 44, wherein at least one of  $R^6$  is  $-OR^4$  and  $R^4$  is alkyl substituted with at least one additional of alkoxy, amino, dialkylamino, and monoalkylamino where the monoalkylamino is further sbustittued with *N*-methylpyrrolidin3-yl and where each alkyl of monoalkylamino and dialkylamino are independently optionally substituted with  $-NH_2$ ,  $-NHCH_3$ , or  $-N(CH_3)_2$ ; or a pharmaceutically acceptable salt or stereoisomer, thereof.

51. **(new)** The compound according to claim 31, selected from Table 3; or a pharmaceutically acceptable salt or stereoisomer, thereof

**Table 3**

Entry	Name	Structure
10	4-{7,8-bis(methoxy)-1-[(4-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**






Entry	Name	Structure
12	4-(7,8-bis(methoxy)-1-{{4-(methoxy)phenyl}methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
13	4-{7,8-bis(methoxy)-1-[(2-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
14	4-{7,8-bis(methoxy)-1-[(3-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
15	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
20	4-[1-{{3,4-bis(methoxy)phenyl}methyl}-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
21	4-(7,8-bis(methoxy)-1-{{3-(methoxy)phenyl}methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
22	4-[1-ethyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
25	4-[1-methyl-6,7,8-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
27	4-[7,8-bis(methoxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
28	4-[1-(1-methylethyl)-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	



**Table 3**

Entry	Name	Structure
29	4-[7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
31	4-[1-methyl-6,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
32	4-[6,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
34	4-[6,7,8-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
35	4-[1-methyl-7,8,9-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
36	4-[1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
37	2-methyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
38	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-(methoxy)phenol	
39	4-{1-methyl-8-(methoxy)-7-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
40	2-(ethoxy)-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
41	2-chloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
42	2-fluoro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
44	2-bromo-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
45	1-{[5-(4-hydroxyphenyl)-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-1-yl]methyl}pyrrolidin-2-one	
54	4-{1-methyl-7-(methoxy)-8-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
55	4-{1-methyl-8-(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
58	4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
59	4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
60	4-[7-(ethyloxy)-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
61	4-{1-methyl-8-(methyloxy)-9-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
63	2-ethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
64	4-(1-methyl-8-(methyloxy)-9-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
65	4-(1-methyl-7-(methyloxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
66	4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
67	1,1-dimethylethyl 4-[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-1-yl]piperidine-1-carboxylate	

**Table 3**

Entry	Name	Structure
69	2-chloro-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
70	2-fluoro-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
71	2-methyl-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
72	2-bromo-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
76	2-[(difluoromethyl)oxy]-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
78	4-[1,9-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
79	4-[6,9-difluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
80	2-bromo-4-{1-methyl-8-(methyloxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
81	2-chloro-4-{1-methyl-8-(methyloxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
82	4-(7,8-bis(methyloxy)-1-[(phenylmethyl)amino]methyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
83	2,5-dimethyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
85	2,5-dichloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
87	2-bromo-4-(1-methyl-8-(methoxy)-9-[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
88	2-chloro-4-(1-methyl-7-(methoxy)-8-[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
89	4-[9-fluoro-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	



Table 3

Entry	Name	Structure
90	4-(1-methyl-8-(methyloxy)-9- {[2-(methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i> ]isoquinolin-5- yl)phenol	
91	2-chloro-4-(1-methyl-8-(methyloxy)-9- {[(1-methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i> ]isoquinolin-5- yl)phenol	
92	4-[6-bromo-1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
93	4-[6-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
94	4-[9-chloro-1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	






### Table 3

Entry	Name	Structure
95	2-chloro-4-[8-{{(1-ethylpiperidin-4-yl)methyl}oxy}-1-methyl-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
96	3-chloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
97	4-(1-methyl-8,9-bis{{2-(methoxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
98	4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
99	2-chloro-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	





**Table 3**

Entry	Name	Structure
100	2-bromo-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
101	2-chloro-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
102	2-bromo-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
103	2-chloro-4-[1-methyl-8-([1-(1-methylethyl)piperidin-4-yl]methyl)oxy)-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
104	4-[9-bromo-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
105	4-[7-chloro-9-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
106	4-[8-{{[(1-acetylpiperidin-4-yl)methyl]oxy}}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
107	4-[9-{{[(1-acetylpiperidin-4-yl)methyl]oxy}}-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-bromophenol	
108	2-chloro-4-(1-methyl-9-(methyloxy)-8-{{[2-(methyloxy)ethyl]oxy}}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
109	4-[7-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	






**Table 3**

Entry	Name	Structure
110	2-chloro-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
111	2-bromo-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
112	2-chloro-4-(1-methyl-8-(methyloxy)-9-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
113	2-bromo-4-(1-methyl-8-(methyloxy)-9-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	






**Table 3**

Entry	Name	Structure
114	3-fluoro-4-[1-methyl-7,8-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
115	2-chloro-4-(1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	
116	2-bromo-4-(1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	
117	2-chloro-4-(1-methyl-7,8-bis{[2-(methoxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	
118	2-bromo-4-(1-methyl-7,8-bis{[2-(methoxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	

**Table 3**






Entry	Name	Structure
120	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
121	2-chloro-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
122	2-bromo-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
123	4-[9-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -benzo[ <i>e</i> ]indazol-5-yl]phenol	
125	3-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
126	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-3-fluorophenol	
127	2-chloro-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
128	2-chloro-4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
129	2-chloro-4-[6-chloro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
130	3-fluoro-4-(1-methyl-9-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	








**Table 3**

Entry	Name	Structure
131	2-chloro-4-(1,7-dimethyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
132	3-fluoro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
133	2-chloro-4-[1-methyl-8-[(1-methylethyl)oxy]-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
134	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(2-methylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
135	2-bromo-5-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
136	4-[7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
137	4-[7,8-bis(methoxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
138	4-{7,8-bis(methoxy)-1-[(methoxy)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}-2-chlorophenol	
139	2-chloro-4-(1-methyl-3 <i>H</i> -[1,3]dioxolo[4,5- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
140	2-chloro-4-(1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
141	2-chloro-4-(1-methyl-9,10-dihydro-3 <i>H</i> ,8 <i>H</i> -[1,4]dioxepino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
142	2-chloro-4-[7-[(difluoromethyl)oxy]-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
143	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
144	2-chloro-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-5-fluorophenol	
145	2-chloro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	

**Table 3**

Entry	Name	Structure
146	2-chloro-5-fluoro-4-(11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinolin-7-yl)phenol	
147	2-chloro-4-[1-methyl-6,7,8-tris(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
148	2-bromo-4-(6,9-difluoro-1-methyl-8-{2-(methyloxy)ethyl}oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)-5-fluorophenol	
149	7-(3-chlorophenyl)-11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinoline	
150	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-8,9-dihydro-3H-[1,4]dioxino[2,3-g]pyrazolo[3,4-c]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
151	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydrofuran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
152	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2 <i>H</i> -pyran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
153	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(2,2,2-trifluoroethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
154	2-chloro-5-fluoro-4-[9-fluoro-1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
155	5-(3-chloro-4-hydroxyphenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

**Table 3**

Entry	Name	Structure
156	6,9-difluoro-5-(2-fluorophenyl)-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinoline	
157	2-chloro-4-{8-[(difluoromethyl)oxy]-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
158	2-chloro-4-(6,11-difluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-5-fluorophenol	
159	4-(1-methyl-3 <i>H</i> -benzo[e]indazol-5-yl)phenol	
160	6-fluoro-7-(2-fluorophenyl)-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinoline	
161	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2 <i>H</i> -pyran-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
162	2-chloro-4-[8-{[2-(ethyloxy)ethyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
164	3-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	
165	2-chloro-5-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i> ]pyrazolo[3,4- <i>c</i> ]isoquinolin-7-yl)phenol	
166	2-chloro-4-[8-(cyclopentyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
167	2-chloro-4-(1-methyl-7-(1-methylethyl)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**

Entry	Name	Structure
168	2-chloro-4-[9-ethyl-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
169	2-chloro-4-(6,9-difluoro-1-methyl-8-[(1-methylpiperidin-4-yl)methyl]oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
170	5-(3-chloro-4-hydroxyphenyl)-8-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-6-ol	
171	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-[(1-methylpiperidin-4-yl)methyl]oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
172	2-chloro-4-(6-fluoro-1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	



**Table 3**

Entry	Name	Structure
173	5-[3-chloro-4-(methyloxy)phenyl]-6-fluoro-1-methyl-7-(methyloxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinoline	
174	5-[3-chloro-4-(methyloxy)phenyl]-8-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-6-ol	
176	2-chloro-4-{6-fluoro-1-methyl-7-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
177	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
178	2-chloro-4-[8-{[2-(diethylamino)ethyl]oxy}-6-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
179	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
182	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
183	2-bromo-4-(6-fluoro-1-methyl-9-(methyloxy)-8-[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
184	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
185	4-(6-fluoro-1-methyl-9-(methyloxy)-8-[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-2-methylphenol	






Table 3

Entry	Name	Structure
186	2-chloro-4-{6,9-difluoro-1-methyl-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
187	2-chloro-4-(8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
188	2-chloro-4-(8-{[2-(diethylamino)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
191	6,9-difluoro-5-(1 <i>H</i> -indol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
193	5-(4-aminophenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

**Table 3**

Entry	Name	Structure
194	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
195	5-(2-amino-1,3-thiazol-5-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
196	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
197	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
198	5-(6-aminopyridin-3-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

Table 3

Entry	Name	Structure
199	5-(5-amino-2-thienyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
200	2-chloro-4-[8-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
201	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[3-(4-methylpiperazin-1-yl)propyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
202	6,9-difluoro-5-(1 <i>H</i> -indol-6-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
203	N-[5-(6,9-difluoro-8-hydroxy-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)-1,3-thiazol-2-yl]acetamide	

**Table 3**

Entry	Name	Structure
206	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
207	4-[8-({2-[butyl(ethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
208	4-[8-{{(2 <i>R</i> )-2-amino-3-methylbutyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
209	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
210	2-chloro-4-[8-{{(1-ethylpiperidin-4-yl)methyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
212	5-(5-amino-1,3,4-thiadiazol-2-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	
213	4-[8-{[(2 <i>R</i> )-2-amino-3,3-dimethylbutyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
214	2-chloro-4-[6-fluoro-1-methyl-9-(methyloxy)-8-({2-[4-(2-methylpropyl)piperazin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
215	2-chloro-4-[8-{{2-(5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
216	2-chloro-4-[6-fluoro-1-methyl-8-({2-[4-(1-methylethyl)piperazin-1-yl]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

**Table 3**

Entry	Name	Structure
217	4-[8-{[2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
218	2-chloro-4-[8-{[2-(1-ethylpiperidin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
219	2-chloro-4-[8-{[2-(diethylamino)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
220	2-chloro-5-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-pyrrolidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
223	2-chloro-4-[6-fluoro-1-methyl-8-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	



**Table 3**

Entry	Name	Structure
224	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-pyrrolidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
225	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-piperidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
226	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-morpholin-4-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
227	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](methyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
228	2-chloro-4-[8-({2-[[2-(diethylamino)ethyl](methyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

**Table 3**

Entry	Name	Structure
229	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](ethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
230	4-[8-[(2-{bis[3-(dimethylamino)propyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
231	2-chloro-4-[6-fluoro-1-methyl-8-({2-[methyl(1-methylpyrrolidin-3-yl)amino]ethyl}oxy)-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
232	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-{(2 <i>S</i> )-2-[(methoxy)methyl]pyrrolidin-1-yl}ethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
233	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(4-pyrrolidin-1-yl)piperidin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
234	2-chloro-4-[8-{[2-(4-cyclohexylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
235	2-[4-(2-{[5-(3-chloro-4-hydroxyphenyl)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-yl]oxy}ethyl)piperazin-1-yl]- <i>N</i> -(1-methylethyl)acetamide	
236	4-[8-{[2-(1,4'-bipiperidin-1'-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
237	2-chloro-4-[6-fluoro-1-methyl-8-{[2-(4-methyl-1,4-diazepan-1-yl)ethyl]oxy}-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
238	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	

**Table 3**




Entry	Name	Structure
239	2-chloro-4-[8-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
240	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-thiomorpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	
241	2-chloro-4-[8-{[2-(2,6-dimethylpiperidin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
242	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(octahydroquinolin-1(2 <i>H</i> )-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl)phenol	
243	4-[8-({2-[bis(1-methylethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	

**Table 3**

Entry	Name	Structure
244	4-[8-[(2-{bis[2-(methyloxy)ethyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]-2-chlorophenol	
245	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl}phenol	

52. (new) A Compound selected from

9	4-[7,8-bis(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]benzene-1,2-diol	
19	4-[7,8-bis(methyloxy)-1-(1-phenylethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	

24	4-[6,7,8-tris(methoxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
26	4-[8-(methoxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-5-yl]phenol	
221	6,9-difluoro-5-(2-imino-3-methyl-2,3-dihydro-1,3-thiazol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i> ]isoquinolin-8-ol	

53. **(new)** A pharmaceutical composition comprising the compound according to claim 31 and a pharmaceutically acceptable carrier.

54. **(new)** A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to claim 31.

55. **(new)** The method according to claim 54, wherein the kinase is ALK.

56. **(new)** The method according to claim 55, wherein modulating the *in vivo* activity of ALK comprises inhibition of ALK.

57. **(new)** A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a

mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 31.

58. **(new)** The method of claim 57 where the disease is an ALK-positive lymphomas, B-cell lymphoma, neuroblastoma, or inflammatory myofibroblastic tumors.